Aspire Private Capital’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Aspire Private Capital’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-67	Closed	-$2K	–	617
2019 Q1	$2K	Hold	67	–	–	﹤0.01%	450
2018 Q4	$2K	Buy	+67	New	+$2.22K	﹤0.01%	424

Other funds holding SBIO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

WIA

Wealthstreet Investment Advisors Dallas, Texas $3.71M AUM 13.1% 1-Year Est. Return

Aspire Private Capital's SBIO Position: Q2 2019 in Review

Aspire Private Capital sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q2 2019, closing a stake of 67 shares — an estimated $2K sold.

Aspire Private Capital first reported a position in SBIO in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 47 funds tracked by Wall St. Rank hold SBIO as of Q2 2019.

Aspire Private Capital reported no remaining ALPS Medical Breakthroughs ETF position as of Q2 2019 after selling out during the quarter.
Aspire Private Capital sold 67 ALPS Medical Breakthroughs ETF shares in Q2 2019, an estimated $2K.
Aspire Private Capital first reported a position in ALPS Medical Breakthroughs ETF in Q4 2018 and held it in 2 quarters.
Aspire Private Capital's ALPS Medical Breakthroughs ETF position peaked at $2K in Q1 2019.
47 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2019.

Based on Aspire Private Capital's 13F filing for Q2 2019, filed 13 Aug 2019.